Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Annales de Dermatologie et de Vénéréologie Année : 2021

Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?

Nicolas Meyer

Résumé

Treatment of patients with melanoma has considerably improved over the past decade and more recently with adjuvant therapies for patients with American Joint Committee on Cancer (AJCC) stage III (loco-regional metastases) or IV (distant metastases) totally resected melanoma, in order to prevent recurrence. In the adjuvant setting, two options are available to patients with BRAFV600-mutant AJCC stage III totally resected melanoma: anti-PD-1 blockers (nivolumab or pembrolizumab) or BRAF plus MEK inhibitors (dabrafenib plus trametinib). In the absence of comparative studies, it is difficult to determine which of these options is best. Our aim was to review published studies focusing on the management of patients with BRAFV600-mutant melanoma in the adjuvant setting. We also reviewed the main clinical trials of BRAF plus MEK inhibitors and immunotherapy in advanced (i.e. unresectable metastatic) BRAF-mutant melanoma in an attempt to identify results potentially affecting the management of patients on adjuvants. More adverse events are observed with targeted therapy, but all resolve rapidly upon drug discontinuation, whereas with immune checkpoint blockers some adverse events may persist. New therapeutic strategies are emerging, notably neoadjuvant therapies for stage III patients and adjuvant therapies for stage II patients; the place of the adjuvant strategy amidst all these options will soon be re-evaluated. The choice of adjuvant treatment could influence the choice of subsequent treatments in neo-adjuvant or metastatic settings. This review will lead clinicians to a better understanding of the different adjuvant treatments available for patients with totally resected AJCC stage III and IV BRAFV600-mutant melanoma before considering subsequent treatment strategies.
Fichier principal
Vignette du fichier
1-s2.0-S0151963821000089-main.pdf (1009.03 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03401797 , version 1 (17-02-2022)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Elisa Funck-Brentano, Nausicaa Malissen, Anissa Roger, Célèste Lebbé, Florian Deilhes, et al.. Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. Annales de Dermatologie et de Vénéréologie, 2021, 148 (3), pp.145-155. ⟨10.1016/j.annder.2020.11.006⟩. ⟨hal-03401797⟩
140 Consultations
169 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More